IPC-klasse
Fullmektig i Norge:
Org.nummer: 982702887
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2021.07.16, US 202163203333 P
2022.01.14, US 202263299753 P
2022.02.01, US 202263305609 P
2022.04.14, US 202263331197 P
2022.05.19, US 202263343975 P
"2022 Arthur E. Weyman Young Investigator's Award Competition Finalists", JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, MOSBY-YEAR BOOK, INC. ST. LOUIS, MO, US, vol. 35, no. 7, 1 July 2022 (2022-07-01), XP087111009, ISSN: 0894-7317, [retrieved on 20220704], DOI: 10.1016/J.ECHO.2022.04.012 (B1)
ANONYMOUS: "NCT04219826 - REDWOOD-HCM: Randomized Evaluation of Dosing With CK-3773274 in HCM", 7 January 2020 (2020-01-07), XP055964895, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04219826> [retrieved on 20220926] (B1)
CHUANG CHIHYUAN ET AL: "Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 19, 4 October 2021 (2021-10-04), US, pages 14142 - 14152, XP055964582, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c01290 (B1)
COATS C J ET AL: "Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 13, no. 15, 26 July 2024 (2024-07-26), pages e035993, XP093222970, ISSN: 2047-9980, DOI: 10.1161/JAHA.124.035993 (B1)
DANIEL JACOBY ET AL: "Treatment of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know - American College of Cardiology", 21 February 2020 (2020-02-21), XP055964663, Retrieved from the Internet <URL:https://www.acc.org/latest-in-cardiology/articles/2020/02/19/18/19/treatment-of-hypertrophic-cardiomyopathy#sort=@commonsortdate%20descending> [retrieved on 20220926] (B1)
ZAMPIERI MATTIA ET AL: "Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives", CURRENT HEART FAILURE REPORTS, CURRENT SCIENCE INC., PHILADELPHIA, PA, US, vol. 18, no. 4, 20 June 2021 (2021-06-20), pages 169 - 179, XP037530915, ISSN: 1546-9530, [retrieved on 20210620], DOI: 10.1007/S11897-021-00523-0 (B1)
MORELLI CRISTINA ET AL: "Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond", EUROPEAN JOURNAL OF INTERNAL MEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 102, 6 May 2022 (2022-05-06), pages 1 - 7, XP087131465, ISSN: 0953-6205, [retrieved on 20220506], DOI: 10.1016/J.EJIM.2022.04.020 (B1)
WO-A1-2019/144041 (B1)
WO-A1-2021/011807 (B1)
WO-A1-2021/011808 (B1)
MARON M S ET AL: "Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 390, no. 20, 13 May 2024 (2024-05-13), US, pages 1849 - 1861, XP093222975, ISSN: 0028-4793, DOI: 10.1056/NEJMoa2401424 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Utgående
EP Registreringsbrev (3210) (PTEP4370116)
|
Innkommende
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
32503261 expand_more expand_less | 2025.03.14 | 7150 | ZACCO NORWAY AS | Betalt |
Valideringsgebyr EP-patent
7150 = 1 X 7150
|